3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol
| Title | Journal |
|---|---|
| Involvement of insulin signalling pathway in methamphetamine-induced hyperphosphorylation of Tau. | Toxicology 20180901 |
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | The Biochemical journal 20130415 |
| Roles of glycogen synthase kinase 3 in Alzheimer's disease. | Current Alzheimer research 20120901 |
| Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120523 |
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | Nature biotechnology 20111101 |
| Identification of new inhibitors of protein kinase R guided by statistical modeling. | Bioorganic & medicinal chemistry letters 20110701 |
| GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro. | Platelets 20110101 |
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | Proceedings of the National Academy of Sciences of the United States of America 20071218 |
| Synthetic small molecules that control stem cell fate. | Proceedings of the National Academy of Sciences of the United States of America 20030624 |
| Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. | Diabetes 20000201 |
| Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. | Diabetes 19990801 |
| Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. | Proceedings of the National Academy of Sciences of the United States of America 19930815 |